Logo

Two Banks Downgrade Serologicals Despite Strong Profit Growth, $1.4B Millipore Buyout

Apr 27, 2006

NEW YORK, April 27 (GenomeWeb News) - Two investment banks today have downgraded Serologicals' stock despite string first-quarter profit growth.

 

Banc of America Securities downgraded the shares to 'Neutral' from 'Buy,' while Matrix Research downgraded the stock to 'Hold' from 'Buy.'

 

As GenomeWeb News reported yesterday, Serologicals said that first-quarter revenues slipped 2.8 percent as R&D spending jumped 11 percent and profits nearly doubled.

 

One day earlier, the company said it would be acquired by Millipore for $1.4 billion.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.